Vethantham V, Rao N, Manley JL (2008) Sumoylation regulates multiple aspects of mammalian poly(A) polymerase function. Genes Dev 22, 499-511 18281463

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K444-sm - PAP-alpha (human) ▲

Modsite: WVIGLVFkkTENSEN SwissProt Entrez-Gene Orthologous residues PAP‑alpha (human): K444‑sm, PAP‑alpha (mouse): K444‑sm, PAP‑alpha (rat): K444‑sm, PAP‑alpha (cow): K444‑sm Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting Disease tissue studied:  bladder cancer Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast), bladder, HeLa (cervical), MBT2 (bladder cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme SUMO LIGASE UBC9 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes SUMO LIGASE UBC9 (human) co-immunoprecipitation, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes siRNA decrease Ubc9 siRNA Downstream Regulation Effect of modification (function):  enzymatic activity, inhibited, protein stabilization

K445-sm - PAP-alpha (human) ▲

Modsite: VIGLVFkkTENSENL SwissProt Entrez-Gene Orthologous residues PAP‑alpha (human): K445‑sm, PAP‑alpha (mouse): K445‑sm, PAP‑alpha (rat): K445‑sm, PAP‑alpha (cow): K445‑sm Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting Disease tissue studied:  bladder cancer Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast), bladder, HeLa (cervical), MBT2 (bladder cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme SUMO LIGASE UBC9 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes SUMO LIGASE UBC9 (human) co-immunoprecipitation, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes siRNA decrease Ubc9 siRNA Downstream Regulation Effect of modification (function):  enzymatic activity, inhibited, protein stabilization

K662-sm - PAP-alpha (human) ▲

Modsite: PHKEEsPkkTKTEED SwissProt Entrez-Gene Orthologous residues PAP‑alpha (human): K662‑sm, PAP‑alpha (mouse): K656‑sm, PAP‑alpha (rat): K656‑sm, PAP‑alpha (cow): K656‑sm Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting Disease tissue studied:  bladder cancer Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast), bladder, HeLa (cervical), MBT2 (bladder cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme SUMO LIGASE UBC9 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes SUMO LIGASE UBC9 (human) co-immunoprecipitation, siRNA inhibition of enzyme DESUMOYLASE SENP1 (human) transfection of inactive enzyme, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes siRNA decrease Ubc9 siRNA Downstream Regulation Effect of modification (function):  enzymatic activity, inhibited, intracellular localization, protein stabilization

K663-sm - PAP-alpha (human) ▲

Modsite: HKEEsPkkTKTEEDE SwissProt Entrez-Gene Orthologous residues PAP‑alpha (human): K663‑sm, PAP‑alpha (mouse): K657‑sm, PAP‑alpha (rat): K657‑sm, PAP‑alpha (cow): K657‑sm Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting Disease tissue studied:  bladder cancer Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast), bladder, HeLa (cervical), MBT2 (bladder cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme SUMO LIGASE UBC9 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes DESUMOYLASE SENP1 (human) transfection of inactive enzyme, transfection of wild-type enzyme SUMO LIGASE UBC9 (human) co-immunoprecipitation, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes siRNA decrease Ubc9 siRNA Downstream Regulation Effect of modification (function):  enzymatic activity, inhibited, intracellular localization, protein stabilization

K736-ac - PAP-alpha (human) ▲

Modsite: ANPIPVIkNsIkLRL SwissProt Entrez-Gene Orthologous residues PAP‑alpha (human): K736‑ac, PAP‑alpha (mouse): K730‑ac, PAP‑alpha (rat): K730‑ac, PAP‑alpha (cow): K730‑ac Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting Disease tissue studied:  bladder cancer Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast), bladder, HeLa (cervical), MBT2 (bladder cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme SUMO LIGASE UBC9 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes SUMO LIGASE UBC9 (human) co-immunoprecipitation, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes siRNA decrease Ubc9 siRNA Downstream Regulation Effect of modification (function):  enzymatic activity, inhibited, protein stabilization

K740-ac - PAP-alpha (human) ▲

Modsite: PVIkNsIkLRLNR__ SwissProt Entrez-Gene Orthologous residues PAP‑alpha (human): K740‑ac, PAP‑alpha (mouse): K734‑ac, PAP‑alpha (rat): K734‑ac, PAP‑alpha (cow): K734‑ac Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting Disease tissue studied:  bladder cancer Relevant cell lines - cell types - tissues:  293 (epithelial), 3T3 (fibroblast), bladder, HeLa (cervical), MBT2 (bladder cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme SUMO LIGASE UBC9 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes SUMO LIGASE UBC9 (human) co-immunoprecipitation, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes siRNA decrease Ubc9 siRNA Downstream Regulation Effect of modification (function):  enzymatic activity, inhibited, protein stabilization